A year and a half after being rebuffed, microcap biotech Trevena is heading back to the FDA in a second bid to win approval for its opioid painkiller.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,